The diverse applications of pancreatic ductal adenocarcinoma organoids

Author(s): Low, RRJ; Lim, WW; Nguyen, PM; Lee, B; Christie, M; Burgess, AW; Gibbs, P; Grimmond, SM; Hollande, F; Putoczki, TL;
Details: Publication Year 2021-10-04,Volume 13,Issue #19,Page 4979
Journal Title: Cancers
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies. While immortalized cancer cell lines and genetically engineered murine models have increased our understanding of PDAC tumorigenesis, they do not recapitulate inter- and intra-patient heterogeneity. PDAC patient derived organoid (PDO) biobanks have overcome this hurdle, and provide an opportunity for the high throughput screening of potential new therapies. This review provides a summary of the PDAC PDO biobanks established to date, and discusses how they have advanced our understanding of PDAC biology. Looking forward, the development of coculturing techniques for specific immune or stromal cell populations will enable a better understanding of the crosstalk that occurs within the tumor microenvironment, and the impact of this crosstalk on treatment response.
Publisher: MDPI
Research Division(s): Personalised Oncology
PubMed ID: 34638463
Publisher's Version: https://doi.org/10.3390/cancers13194979
Open Access at Publisher's Site: https://doi.org/10.3390/cancers13194979
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2021-10-26 10:03:51

Last Modified: 2021-10-29 11:01:30